If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.50
Ask: 317.00
Change: -5.00 (-1.56%)
Spread: 1.50 (0.475%)
Open: 327.00
High: 329.50
Low: 315.00
Prev. Close: 320.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

Tue, 05th Mar 2024 08:57

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

JPMorgan raises Howden Joinery target to 680 (670) pence - 'neutral'

----------

Goldman Sachs cuts Rightmove price target to 660 (667) pence - 'neutral'

----------

Deutsche Bank cuts Standard Chartered target to 860 (910) pence - 'hold'

----------

FTSE 250

----------

JPMorgan places Trustpilot on 'positive catalyst watch'

----------

JPMorgan raises Trustpilot price target to 250 (190) pence - 'overweight'

----------

JPMorgan raises Clarkson price target to 4,320 (4,080) pence - 'overweight'

----------

RBC cuts Pets at Home price target to 260 (265) pence - 'underperform'

----------

RBC cuts Bluefield Solar Income Fund target to 130 (135) pence - 'sector perform'

----------

Berenberg raises Keller price target to 1,300 (1,250) pence - 'buy'

----------

SMALL CAP

----------

Barclays cuts Bank of Ireland to 'equal weight' (over weight) - price target 10.90 (12.80) EUR

----------

RBC raises Oxford BioMedica price target to 740 (720) pence - 'outperform'

----------

RBC cuts Halfords price target to 140 (195) pence - 'sector perform'

----------

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Aug 2022 14:30

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

Read more
26 Jul 2022 11:12

SMALL-CAP WINNERS & LOSERS: Reach and Wickes sink on dark outlook

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Read more
26 Jul 2022 11:09

Oxford BioMedica begins new project and signs license agreement

(Alliance News) - Oxford BioMedica PLC on Tuesday said it started a new project and signed a license and supply agreement.

Read more
26 Jul 2022 08:44

Oxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics

(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.

Read more
22 Jul 2022 10:36

SMALL-CAP WINNERS & LOSERS: Made.com and Hochschild slide again

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
21 Jul 2022 11:13

IN BRIEF: Oxford BioMedica shares up on deal expansion in CAR-T

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Expands its license and clinical supply agreement with Juno Therapeutics Inc, subsidiary of New-York based pharmaceutical industry company Bristol Myers Squibb. It says the expansion relates to the start of two new viral vector programmes for CAR-T therapies. "Oxford Biomedica will receive an undisclosed target nomination fee and potential payments upon the achievement of certain milestones," it notes.

Read more
21 Jul 2022 10:28

SMALL-CAP WINNERS & LOSERS: Go-Ahead suitor pulls out; Costain rises

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
1 Jul 2022 10:41

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
1 Jul 2022 08:56

LONDON MARKET OPEN: Recession fear hits stocks; Oxford Biomedica rises

(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates.

Read more
1 Jul 2022 08:31

Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca

(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 08:07

LONDON BRIEFING: Oxford Biomedica signs new Covid jab deal with Astra

(Alliance News) - Oxford Biomedica on Friday said that it has signed a new three-year agreement with AstraZeneca, which would facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 07:48

LONDON MARKET PRE-OPEN: Oxford Biomedica inks new AstraZeneca jab deal

(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day.

Read more
1 Jul 2022 07:03

Oxford Biomedica signs new Covid vaccine deal with AstraZeneca

(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.

Read more
14 Jun 2022 11:16

US FDA lifts clinical hold on Oxford BioMedica partner's trial

(Alliance News) - Oxford BioMedica PLC on Tuesday noted that the US Food & Drug Administration lifted the clinical hold on Homology Medicines Inc's pheNIX gene therapy trial.

Read more
14 Jun 2022 09:35

Oxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.